Citations

Mayo Clinic

Showing 10 of 108599 citations.

Emerging treatments for primary sclerosing cholangitis
Rodríguez, Eduardo A. , Carey, Elizabeth J. , Lindor, Keith D.

Expert Review of Gastroenterology & Hepatology | February 10, 2017 | Volume: 11 | Issue: 5 | Pages: 451-459

10.1080/17474124.2017.1293524 | PMID 28276816 Get It

Effect of different sustained bone morphogenetic protein‐2 release kinetics on bone formation in poly(propylene fumarate) scaffolds
Olthof, Maurits G.L. , Herrick, James L., Yaszemski, Michael J. , Dhert, Wouter J.A. , Lu, Lichun , Kempen, Diederik H.R.

Journal of Biomedical Materials Research Part B: Applied Biomaterials | February 10, 2017 | Volume: 106 | Issue: 2 | Pages: 477-487

10.1002/jbm.b.33866 | PMID 28186684 Get It

AbstractTo investigate the effect of sustained bone morphogenetic protein‐2 (BMP‐2) release kinetics on bone formation in poly(propylene fumarate) (PPF) scaffolds, different poly(lactic‐co‐glycolic acid) (PLGA) microspheres were used as delivery vehicles. All PPF scaffolds had the same 75% porous structure, while the degradation rate of the embedded PLGA microspheres was changed to tailor BMP‐2 release by varying the lactic‐to‐glycolic acid (L:G) ratio in the copolymer. Four PLGA microsphere formulations with 50/50, 65/35, 75/25, and 85/15 L:G ratios and varying in vivo degradation rates were fabricated. The in vitro and in vivo BMP‐2 release kinetics were determined by analyzing radiolabeled 125I‐BMP‐2. Biological activity of released BMP‐2 was tested using a W20‐17 cell culture model in vitro and a subcutaneous rat model in vivo. Corresponding outcome parameters were defined as capacity to increase the in vitro AP activity in weekly consecutive cell cultures over 14 weeks and the in vivo bone formation after 7 and 14 weeks. The PLGA/PPF composites showed similar biological activity and BMP‐2 release profiles in vitro. In vivo, PPF/PLGA 85:15 composite released significantly less BMP‐2 per time point in the first weeks. Micro‐CT and histological analysis after 7 and 14 weeks of implantation showed bone formation, which significantly increased over time for all composites. No significant differences were seen between the composites. Overall, the results of this study show that small differences in BMP‐2 sustained release had no significant effect on BMP‐2 osteogenic efficacy in PPF/PLGA composites. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 477–487, 2018.
Clinical presentation and treatment outcomes of spinal epidural arteriovenous fistulas
Nasr, Deena M. , Brinjikji, Waleed , Clarke, Michelle J. , Lanzino, Giuseppe

Journal of Neurosurgery: Spine | February 10, 2017 | Volume: 26 | Issue: 5 | Pages: 613-620

10.3171/2016.9.spine16618 | PMID 28186472 Get It

OBJECTIVESpinal epidural arteriovenous fistulas (SEDAVFs) constitute a rare but treatable cause of vascular myelopathy and are a different subtype from the more common Type I spinal dural AVFs. The purpose of this study was to review a consecutive series of SEDAVFs from a single institution and report on the clinical presentations, functional status, and treatment outcomes.METHODSThe authors identified all SEDAVFs treated at their institution from 2005 to 2015. SEDAVFs were defined as spinal AVFs in which the fistulous connection occurred in the epidural venous plexus. The clinical presentation, functional status, immediate treatment outcomes, and long-term neurological outcomes were analyzed.RESULTSTwenty-four patients with SEDAVFs were included in this study. The patients' mean age at presentation was 66.9 years. The most common presenting symptoms were pain and numbness (22 patients, 91.7%), followed by lower-extremity weakness (21 patients, 87.5%). The mean duration of symptoms prior to diagnosis was 11.8 months. Eighteen patients (75.0%) were treated with endovascular therapy alone, 4 (16.7) with surgery, and 2 (8.3%) with a combination of techniques. There was 1 major treatment-related complication (4.2%). Fifteen patients (62.5%) had improvement in disability, and 12 patients (54.5%) had improvement in sensory symptoms.CONCLUSIONSSEDAVFs often present with lower-extremity motor dysfunction and sensory symptoms. With the availability of newer liquid embolic agents, these lesions can be effectively treated with endovascular techniques. Surgery is also effective at treating these lesions, especially in situations where endovascular embolization fails or is not safe and in patients presenting with mass effect from compressive varices.
Faculty Opinions recommendation of 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.
Maher, Jim

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | February 10, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.727261055.793528252 Get It

Pleural Metastasis From Cutaneous Malignant Melanoma
Mytinger, Andrea K., Lim, Kaiser G. , Kern, Ryan , Mullon, John J., Edell, Eric S. , Saeed, A.I. , Kern, Ryan M, Mytinger, Andrea, Kern, R , Lim, Kaiser G

Journal of Bronchology & Interventional Pulmonology | February 10, 2017 | Volume: 25 | Issue: 1 | Pages: 54-56

10.1097/lbr.0000000000000379 | PMID 28195965 Get It

Hypertension Treatment in the Elderly: A Sprint to the Finish
Parsons, Christine, Mookadam, Farouk, Mookadam, Martina , Firth, Christine , Mookadam, Farouk

Future Cardiology | February 10, 2017 | Volume: 13 | Issue: 2 | Pages: 99-102

10.2217/fca-2016-0078 | PMID 28185469 Get It

Effect of gonadotropin‐inhibitory hormone on luteinizing hormone secretion in humans
George, Jyothis Thomas , Hendrikse, Megan , Veldhuis, J. D., Clarke, Iain J. , Millar, Robert P. , George, J T , Anderson, Richard A.

Clinical Endocrinology | February 10, 2017 | Volume: 86 | Issue: 5 | Pages: 731-738

10.1111/cen.13308 | PMID 28186349 Get It

SummaryBackgroundGonadotropin‐inhibitory hormone (GnIH, human homologue of RFRP‐3) suppresses gonadotropin secretion in animal models, but its effects have not been studied in the human.ObjectiveWe tested the hypotheses that exogenous GnIH inhibits LH secretion (i) in postmenopausal women and (ii) in men concurrently administered exogenous kisspeptin.DesignFollowing in vitro and in vivo preclinical studies to functionally characterize the GnIH peptide, a dose‐finding study (human GnIH: 1·5–150 μg/kg/h, iv for 3 h) was undertaken, and 50 μg/kg/h selected for further evaluation. Five postmenopausal women were administered 50 μg/kg/h iv infusion for 3 h or vehicle on two separate days. Four men were administered kisspeptin‐10 (0·3 μg/kg iv bolus) with simultaneous infusion of GnIH (50 μg/kg/h, iv for 3 h) or vehicle.ParticipantsHealthy postmenopausal women (mean age 58 ± 2 years, LH: 30·8 ± 2·9 IU/l, FSH: 78·7 ± 6·4 IU/l, oestradiol: <50 pmol/l) and men (39·8 ± 2·1 years, mean total testosterone 12·1 ± 1·8 nmol/l, LH 2·2 ± 0·2 IU/l).Primary outcomeChange in area under curve (AUC) of LH during GnIHvs vehicle.ResultsDuring GnIH administration in postmenopausal women, LH secretion decreased (ΔAUC: −9·9 ± 1·8 IU/3 h) vs vehicle (ΔAUC: −0·5 ± 1·7 IU/3 h; P = 0·02). Kisspeptin‐10‐stimulated LH responses in men were not affected by GnIH co‐administration (60‐min AUC of LH 6·2 ± 0·8 IU/h with kisspeptin‐10 alone, 6·3 ± 1·0 IU/h, kisspeptin‐10 with GnIH, P = 0·72). Exogenous GnIH was well tolerated, with no adverse events reported.ConclusionsGonadotropin‐inhibitory hormone decreased LH secretion in postmenopausal women in this first‐in‐human study. Kisspeptin‐stimulated LH secretion in men was not inhibited during concomitant administration of GnIH.
Culture-Proven Thorn-Associated Infections in Arizona: 10-Year Experience at Mayo Clinic
Simmons, Sierra C. , Budavari, Adriane I., Kusne, Shimon , Zhang, Nan , Vikram, Holenarasipur R. , Blair, Janis E. , Vikram, Holenarasipur R.

Open Forum Infectious Diseases | February 10, 2017 | Volume: 4 | Issue: 1 | Pages: No page available

10.1093/ofid/ofx017 | PMID 28480288 Get It

AbstractBackgroundThorn injuries are common in the desert Southwest; however, the frequency and microbiology of thorn-associated infections have not been systematically described. Most information comes from case reports describing infections from atypical or environmental microorganisms. Our aim was to summarize the spectrum of thorn-associated infections.MethodsWe conducted a retrospective review of electronic health records for patients presenting to our institution from January 1, 2005 to December 31, 2014 for treatment of thorn-associated injuries and then focused on the patients with cultures.ResultsOf 2758 records reviewed, 1327 patients had thorn-associated injuries; however, only 58 (4.4%) had cultures. Of these patients, 37 (64%) had positive findings; 5 had polymicrobial infection. The most commonly identified organisms were Staphylococcus aureus (n = 22, 59.0%) and coagulase-negative Staphylococcus species (n = 8, 21.6%). Other pathogens included Nocardia species (n = 3, 8.1%), Streptococcus species (n = 2, 5.4%), Gram-negative bacteria (n = 2, 5.4%), Aspergillus species (n = 2, 5.4%), Paecilomyces lilacinus (n = 1, 2.7%), and Candida species (n = 1, 2.7%). There were no infections caused by Pantoea agglomerans, Sporothrix schenckii, or Coccidioides spp.ConclusionsIn contrast to most published case reports, we found that typical cutaneous microorganisms, such as Staphylococcus species, caused the majority of culture-positive, thorn-related infections.
Exercise and trainability: contexts and consequences
Joyner, Michael J. , Joyner, Michael J

The Journal of Physiology | February 10, 2017 | Volume: 595 | Issue: 11 | Pages: 3239-3240

10.1113/jp274031 | PMID 28185284 Get It

Association of Central Arterial Stiffness and Pressure Pulsatility with Mild Cognitive Impairment and Dementia: The Atherosclerosis Risk in Communities Study-Neurocognitive Study (ARIC-NCS)
Meyer, Michelle L. , Palta, Priya, Tanaka, Hirofumi , Wright, Jacqueline D. , Griswold, Michael , Heiss, Gerardo , Deal, Jennifer A. , Knopman, David S. , Mosley, Thomas H.

Journal of Alzheimer’s Disease | February 10, 2017 | Volume: 57 | Issue: 1 | Pages: 195-204

10.3233/jad-161041 | PMID 28222517 Get It

Background: The association of central arterial stiffness and pressure pulsatility with mild cognitive impairment (MCI) and dementia is not well characterized in the population-based setting. Objective: The aim of this study was to quantify the cross-sectional association of arterial stiffness and pressure pulsatility with MCI and dementia among 4,461 older white and black adults from the population-based Atherosclerosis Risk in Communities Study-Neurocognitive Study. Methods: We used race-stratified multinomial logistic regression to evaluate associations of percentile cut points of carotid-femoral pulse wave velocity, central systolic blood pressure, central pulse pressure, and pulse pressure amplification with MCI and dementia versus no cognitive impairment. Results: Among whites, those with carotid-femoral pulse wave velocity or central systolic blood pressure ≥75th percentile had a higher prevalence of MCI compared to participants <75th percentile (conditional odds ratio (OR); 95% confidence interval (CI): 1.27 (1.02, 1.56) and 1.28 (1.04, 1.57), respectively) and those with central pulse pressure ≥75th percentile had a higher prevalence of MCI (OR 1.27 (95% CI: 1.03, 1.58)) and dementia (OR 1.76 (95% CI: 1.06, 2.92) compared to participants <75th percentile. Also among whites, those with pulse pressure amplification ≤25th percentile had a higher prevalence of dementia compared to participants >25th percentile (OR 1.65; (95% CI: 1.01, 2.70). Weaker associations were seen among black participants. Conclusion: Higher arterial stiffness and pulsatility were associated with MCI and dementia in white participants. Longitudinal characterization of the observed associations is warranted to assess whether arterial stiffness and pressure pulsatility predict MCI and dementia among older adults.